Literature DB >> 15570610

Postmarketing surveillance for drug safety in pregnancy: the Organization of Teratology Information Services project.

Robert J Felix1, Kenneth Lyons Jones, Kathleen A Johnson, Carolyn A McCloskey, Christina D Chambers.   

Abstract

BACKGROUND: Although medications are frequently used during pregnancy, premarketing studies exclude pregnant women, with the result that maternal and fetal risks of medications are largely unknown prior to marketing.
METHODS: To demonstrate the feasibility of using Teratology Information Services (TISs) to identify potential subjects who may participate in postmarketing surveillance studies regarding medications taken during pregnancy, maternal characteristics and pregnancy exposure data routinely collected from callers to member agencies of the Organization of Teratology Information Services (OTIS) were pooled for two one-month periods.
RESULTS: A total of 3536 calls inquiring about 7746 different agents were received from pregnant women. Of the 40 medications about which pregnant women most frequently asked, the top two were nonprescription acetaminophen and pseudoephedrine, three were prescription drugs with a U.S. Food and Drug Administration pregnancy label category D designation, and five were prescription antidepressants.
CONCLUSIONS: TISs are well positioned to prospectively ascertain medication exposures in large numbers of pregnant women and may be an exceptional resource for conducting postmarketing surveillance for the safety of medications taken during pregnancy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15570610     DOI: 10.1002/bdra.20090

Source DB:  PubMed          Journal:  Birth Defects Res A Clin Mol Teratol        ISSN: 1542-0752


  3 in total

1.  Drug exposure during the periconceptional period: a study of 1793 women.

Authors:  Elisabeth Autret-Leca; Jean Deligne; Joffray Leve; Agnès Caille; Hawaré Cissoko; Annie Pierre Jonville-Bera
Journal:  Paediatr Drugs       Date:  2011-10-01       Impact factor: 3.022

2.  Safe Expectations: Current State and Future Directions for Medication Safety in Pregnancy Research.

Authors:  Mollie E Wood; Susan E Andrade; Sengwee Toh
Journal:  Clin Ther       Date:  2019-09-25       Impact factor: 3.393

3.  Counseling about medication-induced birth defects with clinical decision support in primary care.

Authors:  Eleanor Bimla Schwarz; Sara M Parisi; Steven M Handler; Gideon Koren; Grant Shevchik; Gary S Fischer
Journal:  J Womens Health (Larchmt)       Date:  2013-08-09       Impact factor: 2.681

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.